OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, has announced the appointment of Alexander Gebauer to the Company’s Management Board. Dr Gebauer will lead the clinical development efforts of OMEICOS Therapeutics GmbH. He has also been appointed to Chief Executive Officer and Chairman of the Board of the recently founded US-based subsidiary, OMEICOS Ophthalmics. Prior to joining OMEICOS Therapeutics, Dr. Gebauer served in a multitude of R&D roles, including Managing Director, President of Global R&D, Chief Scientific Officer and other executive committee positions at several international pharmaceutical companies such as Sun Pharmaceuticals, Ranbaxy Laboratories., Merz Pharmaceuticals Hoechst, Aventis and Sanofi.
